Roundtable
Focus on Gastric, GEJ, and Esophageal Cancers
The panel launches into a discussion of practice-changing data, focusing on MATTERHORN and its impact on disease management.
The panel takes a deep dive into the evolving role of IO in resectable GE cancer, with a focus on the results of MATTERHORN.
The panel delves into the implications of recent data on IO in the perioperative, adjuvant treatment of upper GI cancers.
The panel shifts focus to the 1L treatment of metastatic gastroesophageal cancers, exploring biomarker testing strategies.
The panel concludes with a discussion on treatment strategies for metastatic esophageal squamous cell carcinoma.
Advertisement
Focus on Advanced HCC
The panel focuses on how they approach regimen selection amid new options like ipi/nivo, atezo/bev, and durva/treme.
The panel examines the role of len/pembro, weighing its clinical activity against the backdrop of a negative phase III trial.
The panel explores how treatment goals in advanced HCC have evolved, in light of unpredictable long-term responders to IO.
The panel highlights the lack of definitive data and the rationale behind using second-line TKIs or ICIs.
The panel ends with challenges and current limitations of biomarkers in HCC, emphasizing the need for more effective tools.
Focus on Metastatic CRC
The panel dives into the role of biomarker testing in CRC, noting how next-gen sequencing and MSI testing are essential.
The panel explores the evolving treatment landscape for patients with MSI-high metastatic colorectal cancer.
The panel discusses strategies for IO in CRC, including the ATOMIC trial and adoption of neoadjuvant checkpoint inhibition.
The panel highlights the BREAKWATER study and explores practical considerations for therapy before biomarker results.
The panel concludes with an in-depth discussion on the evolving role of ctDNA in colorectal cancer management.
Focus on Upper GI
Personalized Care in Gastric and Esophageal Cancers: Biomarkers, Diagnosis, and Treatment Approaches
The panel focuses on the management of gastroesophageal cancers, highlighting differences in presentations across regions.
The panel explores advancements in early-stage esophageal cancer, emphasizing the paradigm shift toward FLOT chemotherapy.
The panel covers updates on 1L treatments for metastatic gastric cancer, including the recent approval of tislelizumab.
The panel considers tislelizumab amid existing PD-1 inhibitors, zolbetuximab for Claudin-positive patients, and more.
The panel covers ASPEN-O6 results, excitement around ADCs in late-line HER-2 and Claudin-positive cancers, and more.
Focus on Gastric Cancer
An expert panel of GI oncologists debates recent advancements in biomarker-driven strategies for GI cancer care.
The panelists discuss the impact of biomarkers on personalized gastric cancer care, including ctDNA, claudin 18.2, and PD-L1.
In part three of their discussion, the panel explores the role of ADCs in treating gastric and esophageal cancers.
The panel discusses considerations around treating peritoneal gastric cancer, including the role of HIPEC.
Focus on Colorectal Cancer
The panel focuses on the evolution of CRC treatment paradigms, including advances in chemo, biologic agents, and more.
The panel swaps opinions on advancements in EGFR and KRAS inhibitors, as well as the importance of NGS and liquid biopsy.
The panel details strategies for managing oligometastatic CRC, emphasizing the importance of a multidisciplinary approach.
The panel expands on the incorporation of ctDNA in the CRC adjuvant setting, highlighting its prognostic value.
The panel explores sequencing challenges for therapies like fruquintinib, TAS-102, and sotorasib for colorectal cancer.
The panel concludes with the challenges of implementing cutting-edge research into colorectal cancer care and practice.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.